Zuberitamab

Phase 3Monoclonal antibody

BBioRay Pharmaceutical Co., Ltd.

Zuberitamab is one of 139 small molecule programs targeting Nephrotic Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nephrotic SyndromeNot yet recruiting

Mantle Cell LymphomaActive, not recruiting

TreatmentActive, not recruiting

EBV InfectionNot yet recruiting

Follicular LymphomaNot yet recruiting

Nephrotic SyndromePhase 3

Not yet recruiting

Mantle Cell LymphomaPreclinical

Active, not recruiting

TreatmentPhase 2

Active, not recruiting

EBV InfectionPhase 2

Not yet recruiting

Follicular LymphomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

332 competitors in Treatment

#DrugCompanyPhaseTrials

Zuberitamab

BBioRay Pharmaceutical Co., Ltd.

Phase 3

1 2

Dexilant

Takeda

Preclinical

2 3

Emtriva

Gilead

Preclinical

1 4

Lamprene

Novartis

Preclinical

1 5

Theo-Dur

Pfizer

Preclinical

1 6

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 7

Valium

Akero Therapeutics

Preclinical

2 8

Sirturo

WWim Janssens

Preclinical

1 9

Lotemax

PPharmos

Preclinical

1 10

Norpramin

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Membranous Nephropathy

NCT06642909

Q3 2028

N/ARecruiting

Mantle Cell Lymphoma

NCT07257510

Q4 2028

Phase 3Not yet recruiting

Nephrotic Syndrome

NCT07765914

Q4 2029

Phase 2Active, not recruiting

Treatment

NCT07480863

Phase 3Not yet recruiting

Primary Membranous Nephropathy

NCT07830433

Clinical

Trials by Indication[1]

Membranous Nephropathy1 trial

A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

Active, not recruiting·BBioRay Pharmaceutical Co., Ltd.·Phase 2·NCT06642909·135 enrolled

EBV Infection1 trial

Zuberitamab for EBV Infection Post-Allo-HSCT

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07261215·20 enrolled

Mantle Cell Lymphoma1 trial

Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma

Recruiting·PPeking University Third Hospital·N/A·NCT07257510·34 enrolled

Follicular Lymphoma1 trial

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT06757894·50 enrolled

Treatment1 trial

Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZL

Active, not recruiting·—·Phase 2·NCT07480863·65 enrolled

2 more indications

Primary Membranous Nephropathy1 trial

Evaluation of the Efficacy of Zuberitamab Injection in Patients With Primary Membranous Nephropathy

Not yet recruiting·BBioRay Pharmaceutical Co., Ltd.·Phase 3·NCT07830433·150 enrolled

Nephrotic Syndrome1 trial

Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter Randomized Controlled Trial

Not yet recruiting·CChildren's Hospital of Fudan University·Phase 3·NCT07765914·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Zuberitamab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zuberitamab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zuberitamab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioRay Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: BBioRay Pharmaceutical Co., Ltd.

Zuberitamab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Q4 2028

Q4 2029

Trials by Indication[1]

Membranous Nephropathy1 trial

EBV Infection1 trial

Mantle Cell Lymphoma1 trial

Follicular Lymphoma1 trial

Treatment1 trial

Primary Membranous Nephropathy1 trial

Nephrotic Syndrome1 trial

References

Drug Info

Quick Facts

Related News